Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Hepatitis C Therapy Useless for Some

Those who don't respond at first not helped by maintenance treatment, study shows


Related Encyclopedia
 border=
Abscess
Actinomycosis
Acute Myeloid Leukemia (Adult)
Adenocarcinoma of the Lung and Brain Metastases
More...

Related Healthscout Videos
 border=
Optimistic Healing
Cancer Treatment for Any Size
Fever Kills Cancer
Cancer Detection
More...

Related Animations
 border=
Breast Self-Exam Video
Colon Cancer
Hepatitis
More...

Related Drug Information
 border=
Abilify
Augmentin
Bactroban Cream
Bactroban Ointment
More...

Related News Articles
 border=
Hormone Therapy & Breast Cancer
Study: High Breast Density Increases Risk for Cancer Recurrence
Pap Smear Alternative no Improvement
Risky Breast Cancer Drug OK'd by Canadian Cardiologists
More...

WEDNESDAY, Dec. 3 (HealthDay News) -- Maintenance therapy using low-dose peginterferon doesn't help patients with advanced chronic hepatitis C who haven't responded to an initial round of treatment, new research suggests.

The study also showed a surprising health decline in patients with liver disease over the course of four years.

Text Continues Below



"This course of treatment had been adopted by a number of doctors in the U.S. and in other countries, though it had yet to be proven to work. That practice should be stopped, based on the results of this trial. There is no rationale for using maintenance therapy. The treatment is clearly ineffective," study author Dr. Adrian Di Bisceglie, chief of hepatology and co-director of the Liver Center at Saint Louis University, said in a university news release.

About half of patients with chronic hepatitis C fully recover after an initial course of peginterferon and ribavirin antiviral therapy that can last from six months to a year. Other patients (non-responders) may show improvement, but the virus isn't eliminated.

The study included 1,050 non-responder patients with advanced liver disease. Half of them received low doses of peginterferon for 3.5 years to try to suppress the hepatitis C virus and slow progression of liver disease. The other patients were assigned to a control group.

After four years, 30 percent of patients in both groups had developed liver failure, liver cancer, or had died. Among those who had milder cirrhosis at the start of the study, 10 percent to 12 percent developed severe liver disease. Both of these findings surprised the researchers.

"Hepatitis patients in these circumstances got very ill over the course of four years, surprisingly so. The lesson we learned is that once chronic hepatitis C gets to the stage of advanced fibrosis, patients can decline rapidly," De Bisceglie said.

The study was published in the Dec. 4 issue of the New England Journal of Medicine.

About 4 million people in the United States are infected with hepatitis C, and 10,000 to 12,000 of them die each year. Hepatitis C is caused by virus that's transmitted through direct contact with an infected person's blood.

More information

The U.S. Centers for Disease Control and Prevention has more about hepatitis C.



-- Robert Preidt

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 12/3/2008

Related Links
 border=
From Healthscout's partner site on cholesterol, CholesterolNetwork.com
VIDEO: Open Arteries with a Cancer Drug
ONLINE TEST: Take our Home Body Fat Test!
QUIZ: Recommended Daily Calories and Fat





SOURCE: Saint Louis University, news release, Dec. 3, 2008


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy